Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

Thyroid Eye Disease Clinical Trial

Official title:

Efficacy and Safety of Tocilizumab in Patients With Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease: Open, Prospective, Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06367517
• Other study ID #: KB/114/2022
• Status: Recruiting
• Start date: May 20, 2021
• Est. completion date: May 20, 2026

Study information

• Verified date: April 2024
• Source: Medical University of Warsaw
• Contact: Tomasz Bednarczuk, MD, PHD
• Phone: 48225992975
• Email: tomasz.bednarczuk[@]wum.edu.pl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate the efficacy and safety of Tocilizumab as second/third line treatment in patients with Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease.

Description:

Graves' Orbitopathy (GO) is an autoimmune disease that involves orbital tissues, leading to temporary or permanent damage to the eye. Although GO is a rare condition, it negatively affects the quality of life in the majority of patients. In the majority of european centers, high-dose intravenous glucocorticoid (GCs) therapy remains the first-line treatment in patients with active, moderate-to-severe GO. However, GCs are effective in only 45-60% of patients, with a high probability of diseases relapse (10-40%) or disease progression to dysthyroid optic neuropathy (up to 10%). Due to limited efficacy of GCs, unpredictable relapses and progression of GO, the management of GO remains a challenge.

A few studies have demonstrated that interleukin-6 (IL-6) blockade with tocilizumab (TCZ) is effective in GC-refractory GO. However, the long-term outcomes of TCZ remain scarce.

Therefore, the investigators are planning to assess the therapy with Tocilizumab, regarding clinical outcomes and adverse events. The investigators plan to include a total of 30 patients with active, moderate-to-severe, corticosteroid-resistant GO over a period of approximately 4 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: May 20, 2026
• Est. primary completion date: May 20, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Written informed consent

• Male or female, 18-80 years old

• Patients with active (Clinical Activity Score = 3 in 7-item scale) and moderate-to-severe GO, diagnosed according to the EUGOGO guidelines, after the completion of MP pulse treatment, WITH

o Deterioration of GO (in 1 or 2 eyes) when two of the following occurred:

• increase in palpebral aperture by at least 2 mm;

• deterioration in CAS by at least 2 points (7-point CAS)

• increase in exophthalmos by at least 2 mm;

• worsening of diplopia (appearance or change in the degree)

• worsening in ocular motility by 8o

o Incomplete response in both eyes to intravenous methylprednisolone pulse therapy; defined changes smaller than previously defined in any of the mentioned parameters.

• Euthyroid for at least 6-8 weeks (serum free hormone concentrations within 30% of normal range) on either anti-thyroid medications (tyonamides) to control hyperthyroidism or L-thyroxine for replacement therapy for hypothyroidism.

• Negative pregnancy test in women of fertile age.

• All female patients of fertile age must use a reliable contraceptive method to prevent pregnancy during the study period, and at least during a period of six months following the last dose of the investigational medicinal product.

Exclusion Criteria:

• Signs of sight-threatening TED (severe keratopathy, optic neuropathy)

• Pregnant or breastfeeding woman or woman planning to become pregnant during the study

• Patients who could need treatment with radioactive iodine or thyroidectomy during the study

• Treatment with any biological therapy at any time.

• Active infection.

• History of recurrent clinically significant infection or recurrent bacterial infections.

• Positive quantiferon without documentation of treatment for tuberculosis (TB) infection or documentation of no need for such therapy.

• Required management of infections, as follows: currently on any suppressive therapy for a chronic infection, hospitalization for treatment of infection within 60 days before Day 0, use of parenteral antibiotics within 60 days before Day 0, use of oral antibiotics within 30 days before Day 0.

• History of intestinal ulceration or diverticulitis

• Patients with a history of chronic liver disease or liver disorders: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) above 5 times upper limit of normal (ULN)

• HBsAg positive test.

• HBcAb positive test, regardless of HBsAb status, will undergo HBV DNA which, if positive, will be excluded. HbcAb positive, HbsAg negative patients with undetectable HBV DNA will receive antiviral prophylaxis throughout the immunosuppressive therapy.

• Hepatitis C antibody positive test at screening.

• Positive test for Human Immunodeficiency Virus (HIV) antibody at screening or historically. Denied consent to HIV testing.

• Absolute neutrophil count (ANC) < 2.0 × 109/L or a platelet count < 100×103/µL

• Alkaline phosphatase and bilirubin>1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is<35%).

• Cardiovascular or cerebrovascular disease clinically significant.

• Other serious chronic illness (including uncontrolled diabetes mellitus, renal disease, pulmonary disease, major depression).

• History of sarcoidosis.

• Primary or secondary immunodeficiency.

• History of IgE-mediated or non-IgE-mediated hypersensitivity.

• History of reactions or anaphylactic allergic severe human monoclonal antibodies, humanized or murine.

• Administration of live vaccines given within 30 days prior to administration of (Day 0) or concurrently with tocilizumab (during study).

• Splenectomy.

• Current drug or alcohol abuse or dependence.

Related Conditions & MeSH terms

• Eye Diseases
• Graves Ophthalmopathy
• Ophthalmopathy
• Orbitopathy, Graves
• Thyroid Diseases
• Thyroid Eye Disease

Intervention

Drug:
• Tocilizumab
Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks

Locations

Country	Name	City	State
Poland	Department of Internal Medicine and Endocrinology, Medical University of Warsaw	Warsaw

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Warsaw

Country where clinical trial is conducted

Poland, 

References & Publications (5)

Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marino M, Vaidya B, Wiersinga WM; EUGOGO dagger. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479. — View Citation

Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts I, Salvi M, Stan MN. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022 Dec;32(12):1439-1470. doi: 10.1089/thy.2022.0251. Epub 2022 Dec 8. — View Citation

Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodriguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, Espana Gregori E, Sales-Sanz M; Tocilizumab in Graves Orbitopathy Study Group. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol. 2018 Nov;195:181-190. doi: 10.1016/j.ajo.2018.07.038. Epub 2018 Aug 4. — View Citation

Rymuza J, Kus A, Bialas-Niedziela D, Turczynska M, Kecik D, Bednarczuk T. Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab. Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224. — View Citation

Sawicka-Gutaj N, Bednarczuk T, Daroszewski J, Waligorska-Stachura J, Miskiewicz P, Sowinski J, Bolanowski M, Ruchala M. GO-QOL--disease-specific quality of life questionnaire in Graves' orbitopathy. Endokrynol Pol. 2015;66(4):362-6. doi: 10.5603/EP.2015.0046. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease improvement	Proportion of patients improved at 16, 24 and 48 weeks as assessed by a composite ophthalmic score. A response to treatment will be considered positive in the case of an improvement of at least 2 of the following features in 1 eye, without concomitant deterioration in the other eye: decrease in eyelid aperture by at least 2 mm measured with a ruler; decrease in proptosis by at least 2 mm measured with Hertel Exophthalmometer; increase in eyelid motility by at least 8° assessed by ophthalmologist or improvement of Bahn-Gorman diplopia score (Grade I - intermittent diplopia, Grade II - Inconstant diplopia, Grade III - Constant diplopia); decrease in 7-item (spontaneous retrobulbar pain, pain on attempted upward or downward gaze, redness of eyelids, redness of conjunctiva, sweeling of caruncle or plica, swelling of eyelids, swelling of conjunctiva) clinical activity score (CAS) by at least 2 points.	at 16, 24 and 48 weeks
Primary	Improvement of quality of life	Improvement of quality of life according to the disease-specific quality of life questionnaire in Graves' orbitopathy (GO-QoL) at 16, 24 and 48 weeks. All Go-QoL questions will be scored as 'severely limited' (one point), a 'little limited' (two points), or 'not limited at all' (three points). The questions will be transformed from 0 to 100 by the following formula: total score= (raw score- 8)/16 x100. An improvement in QoL wil be considered, if there will be an increase of 6 or more points on either one (or both) the GO-QoL scales (functioning and appearance);	at 16, 24 and 48 weeks
Secondary	Disease inactivation	Proportion of patients achieving response in reduction of clinical activity score (CAS) defined as reduction of = 2 points from baseline in the study eye without deterioration (= 2 point increase) of CAS in the fellow eye	at 16, 24 and 48 weeks
Secondary	Proportion of patients achieving response in specific GO signs and symptoms	reduction of proptosis of least 2 mm without deterioration (= 2 mm increase) of proptosis in the fellow eye measured with Hertel Exophthalmometer.; diplopia; proportion of participants with baseline diplopia > 0 and a reduction of = 1 grade assessed according to Bahn-Gorman diplopia score (Grade I - intermittent diplopia, Grade II - Inconstant diplopia, Grade III - Constant diplopia); ocular motility; an increase of at least 8° assessed by ophthalmologist; palpebral aperture; an increase of at least 2 mm measured with a ruler; reduction in spontaneous or gaze-evoked retrobulbar pain - a binary scale (yes/no); reduction in swelling of eyelids (severe/moderate/mild), redness of eyelids (yes/no), redness of conjunctiva (yes/no), sweeling of caruncle or plica (yes/no), swelling of conjunctiva (yes/no)	at 16, 24 and 48 weeks
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Incidence of adverse events, with severity determined according to NCI CTCAE v5.0	from 0 to 16 weeks
Secondary	Decrease in concentration of thyrotropin receptor antibodies	Decrease in concentration of thyrotropin receptor antibodies	at 4, 8, 12, 16, 24 and 48 weeks
Secondary	Decrease in levels of proinflammatory cytokines	Decrease in serum levels of interleukin-17a and interleukin-23	at 4, 8, 12, 16, 24 and 48 weeks
Secondary	Number of the rehabilitative surgeries performed after immunosuppressive therapy	Rehabilitative surgery includes orbital decompression, squint surgery, lid lengthening, and blepharoplasty/browplasty	at 48 weeks
Secondary	The rate of disease relapse	Proportion of patients with worsening of symptoms associated with GO after a period of improvement or stability. The relapse of the disease will be noted in case of a deterioration of at least 2 of the following features in 1 eye: increase in eyelid aperture by at least 2 mm measured with a ruler ,; increase in exophthalmos by at least 2 mm measured with Hertel Exophthalmometer,; decrease in eyelid motility by at least 8° assessed by ophthalmologist or deterioration of = 1 grade in Bahn-Gorman diplopia score (Grade I - intermittent diplopia, Grade II - Inconstant diplopia, Grade III - Constant diplopia),; increase in 7-item (spontaneous retrobulbar pain, pain on attempted upward or downward gaze, redness of eyelids, redness of conjunctiva, sweeling of caruncle or plica, swelling of eyelids, swelling of conjunctiva) clinical activity score (CAS) by at least 2 points.	at 48 weeks
Secondary	Decrease in proptosis by at least 2 mm assessed using magnetic resonance imaging (MRI)	Measurement of exophthalmos (the distance between the interzygomatic line and the anterior surface of the globe - corneal apex) on axial T2W orbital MRI images performed at week 16 in comparison to baseline.	at 16 weeks